A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.

Sheng Yang(Fujian Medical University), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Haifeng Song(Anhui Medical University), Yan Sun(Peking University), Lihou Dong(Academy of Military Medical Sciences), Ying Han(Fujian University of Traditional Chinese Medicine), Hui Feng(Boston University), Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaohong Han(Chinese Academy of Medical Sciences & Peking Union Medical College)
Journal of Clinical Oncology
May 20, 2017
10.1200/jco.2017.35.15_suppl.e14581
Cited by 2

Related Papers

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350